What ImmunoACT does
Founded in 2018, ImmunoACT operates in Health Tech offering gene-modified cell therapies, specifically CAR-T cell therapy for treating certain B-cell malignancies. The company was spun out from IIT-Bombay and has launched Indias first CAR-T cell therapy. With a rapidly expanding pipeline, ImmunoACT focuses on providing affordable access to these novel therapies. Its mission centres on increasing accessibility to innovative cancer treatments in the Indian healthcare landscape.
Who runs it
Funding and finances
Why this matters to you: funding stage is a rough proxy for how long the runway is and how much structure to expect. It is not a promise, and a profitable bootstrapped company can be the safer bet.
Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.
Questions and experiences
Nobody has asked anything about ImmunoACT yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.
Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.